Table 2 Results of overall meta-analysis

Long-term outcomes

5-years disease-free survival

18[10, 11, 13–16, 24, 28, 31–40]

1275

1567

32.1%

30.0%

1.19 (0.93, 1.53)

0.17

0.02

5-years overall survival

16[11, 12, 14–16, 24, 28, 29, 31, 34–40]

1038

1463

40.2%

45.2%

0.85 (0.59, 1.22)

0.37

<0.01

Total recurrence

11[10, 14, 16, 24, 30, 32, 35, 36],[38–40]

673

917

61.0%

58.4%

0.99 (0.72, 1.36)

0.95

0.08

Intrahepatic recurrence

12[10–12, 14, 16, 24, 29, 30, 32, 35],[36, 39]

660

797

51.2%

53.6%

0.84 (0.67, 1.05)

0.12

0.23

Extrahepatic recurrence

9[10, 14, 16, 24, 30, 32, 35, 36],[39]

519

591

12.9%

10.3%

1.30 (0.88, 1.92)

0.19

0.33

Short-term outcomes

Overall morbidity

11[10–12, 14, 16, 24, 29, 30, 35, 36],[40]

583

803

28.9%

26.8%

1.02 (0.80, 1.32)

0.85

0.42

Liver failure

6[11, 12, 14, 16, 29, 36]

337

457

5.9%

6.3%

1.06 (0.57, 1.96)

0.86

0.31

Bile leakage

6[12, 14, 16, 29, 35, 36]

371

569

3.5%

2.8%

1.12 (0.53, 2.35)

0.77

0.80

Pleural effusion

4[12, 29, 35, 36]

300

485

7.0%

8.0%

0.93 (0.53, 1.65)

0.24

0.26

Ascites

3[29, 35, 36]

269

378

6.3%

6.1%

0.98 (0.51, 1.89)

0.96

0.16

Intra-abdominal abscess

5[11, 14, 29, 35, 36]

348

451

2.5%

1.3%

1.66 (0.63, 4.40)

0.31

0.58

Wound infection

5[12, 14, 16, 35, 36]

311

501

3.2%

2.5%

1.11 (0.48, 2.53)

0.81

0.35

Postoperative bleeding

3[11, 12, 36]

206

305

3.3%

2.9%

1.25 (0.41, 3.81)

0.69

0.63

Stress ulcer bleeding

3[12, 29, 35]

180

332

1.1%

1.2%

1.31 (0.29, 5.92)

0.73

0.74

Pneumonia

4[11, 12, 14, 35]

199

337

4.0%

2.1%

1.64 (0.60, 4.46)

0.33

0.23

Mortality

16[10–12, 14–16, 24, 28–30, 33–36, 38, 40]

1100

1325

4.1%

3.1%

1.25 (0.80, 1.97)

0.33

0.85